Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study.

Abstract

OBJECTIVE:

To compare etanercept (anti-tumor necrosis factor-α) with intraarticular (IA) corticosteroid injections to treat rheumatoid arthritis (RA).

METHODS:

Patients with RA who had persistent monoarthritis received etanercept or IA corticosteroid injections. Efficacy was compared at Weeks 4 and 24.

RESULTS:

Thirty-four patients were included (8 dropped out). Mean age was 58.8 years. No difference between groups was found at Weeks 4 or 24, but both groups showed significant improvement at Weeks 4 and 24 compared to baseline.

CONCLUSION:

Etanercept and IA steroid injections resulted in significant improvement at Week 4 that persisted to Week 24. There was no significant difference in outcome between the groups.

• Authors: Christian H Roux, Veronique Breuil, Laure Valerio, Nicolas Amoretti, Olivier Brocq, Christine Albert, Christian Grisot, Yacine Allam, Patrick Chevalier, Christian Pradier, Lianna Euller-Ziegler
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 38 Issue 6 Pg. 1009-11 (Jun 2011) ISSN: 0315-162X [Print] Canada
• PMID: 21406499 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Adrenal Cortex Hormones
• Antirheumatic Agents
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Etanercept

Topics

• Adrenal Cortex Hormones (administration & dosage, adverse effects, therapeutic use)
• Antirheumatic Agents (administration & dosage, adverse effects, therapeutic use)
• Arthritis, Rheumatoid (blood, diagnostic imaging, drug therapy)
• Blood Sedimentation
• Dose-Response Relationship, Drug
• Double-Blind Method
• Etanercept
• Female
• Humans
• Immunoglobulin G (administration & dosage, adverse effects, therapeutic use)
• Injections, Intra-Articular
• Longitudinal Studies
• Male
• Middle Aged
• Pilot Projects
• Receptors, Tumor Necrosis Factor (administration & dosage, therapeutic use)
• Treatment Outcome
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)
• Ultrasonography